Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16151
Title: Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)
Authors: Averbuch, Diana
Cordonnier, Catherine
Livermore, David M.
Mikulska, Malgorzata
Orasch, Christina
Viscoli, Claudio
GYSSENS, Inge 
Kern, Winfried V.
Klyasova, Galina
Marchetti, Oscar
Engelhard, Dan
Akova, Murat
Issue Date: 2013
Source: HAEMATOLOGICA, 98 (12), p. 1836-1847
Abstract: The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4th European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists.
Notes: Averbuch, D (reprint author), Hadassah Hebrew Univ, Med Ctr, Pediat Infect Dis Unit, Jerusalem, Israel. adiana@hadassah.org.il; engelhard@hadassah.org.il
Document URI: http://hdl.handle.net/1942/16151
ISSN: 0390-6078
e-ISSN: ****-****
DOI: 10.3324/haematol.2013.091330
ISI #: 000328545500011
Category: A1
Type: Journal Contribution
Validations: ecoom 2015
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
averbuch 1-2.pdfpublished version651.81 kBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

82
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

79
checked on May 14, 2022

Page view(s)

44
checked on May 20, 2022

Download(s)

76
checked on May 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.